Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analyses

被引：57

作者：

Frye M.A. ^{[1
]}

McElroy S.L. ^{[3
,4
]}

Fuentes M. ^{[5
]}

Sutor B. ^{[1
]}

Schak K.M. ^{[1
]}

Galardy C.W. ^{[1
]}

Palmer B.A. ^{[1
]}

Prieto M.L. ^{[6
]}

Kung S. ^{[1
]}

Sola C.L. ^{[1
]}

Ryu E. ^{[2
]}

Veldic M. ^{[1
]}

Geske J. ^{[2
]}

Cuellar-Barboza A. ^{[7
]}

Seymour L.R. ^{[1
]}

Mori N. ^{[3
]}

Crowe S. ^{[8
]}

Rummans T.A. ^{[1
,9
]}

Biernacka J.M. ^{[1
,2
]}

机构：

[1] Department of Psychiatry and Psychology, Mayo Clinic, 200 First St SW, Rochester, 55905, MN

[2] Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN

[3] Lindner Center of HOPE, Mason, OH

[4] Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH

[5] Department of Psychiatry, Universite Desarrollo and Clinca Allemana, Santiago

[6] Department of Psychiatry, Universidad de los Andes, Santiago

[7] Department of Psychiatry, Autonomous University of Nuevo Leon, Monterrey

[8] Department of Psychiatry, University of Minnesota, Minneapolis, MN

[9] Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL

来源：

International Journal of Bipolar Disorders | / 3卷 / 1期

关键词：

Biobank; Bipolar disorder; Phenotype;

D O I：

10.1186/s40345-015-0030-4

中图分类号：

学科分类号：

摘要：

Background: We aimed to establish a bipolar disorder biobank to serve as a resource for clinical and biomarker studies of disease risk and treatment response. Here, we describe the aims, design, infrastructure, and research uses of the biobank, along with demographics and clinical features of the first participants enrolled. Methods: Patients were recruited for the Mayo Clinic Bipolar Biobank beginning in July 2009. The Structured Clinical Interview for DSM-IV was used to confirm bipolar diagnosis. The Bipolar Biobank Clinical Questionnaire and Participant Questionnaire were designed to collect detailed demographic and clinical data, including clinical course of illness measures that would delineate differential phenotypes for subsequent analyses. Blood specimens were obtained from participants, and various aliquots were stored for future research. Results: As of September 2014, 1363 participants have been enrolled in the bipolar biobank. Among these first participants, 69.0 % had a diagnosis of bipolar disorder type I. The group was 60.2 % women and predominantly white (90.6 %), with a mean (SD) age of 42.6 (14.9) years. Clinical phenotypes of the group included history of psychosis (42.3 %), suicide attempt (32.5 %), addiction to alcohol (39.1 %), addiction to nicotine (39.8 %), obesity (42.9 %), antidepressant-induced mania (31.7 %), tardive dyskinesia (3.2 %), and history of drug-related serious rash (5.7 %). Conclusions: Quantifying phenotypic patterns of illness beyond bipolar subtype can provide more detailed clinical disease characteristics for biomarker research, including genomic-risk studies. Future research can harness clinically useful biomarkers using state-of-the-art research technology to help stage disease burden and better individualize treatment selection for patients with bipolar disorder. © 2015, Frye et al.

引用

页数：7

共 32 条

[1]

Diagnostic and statistical manual of mental disorders: DSM-IV-TR, (2000)

[2]

Baum A.E., Akula N., Cabanero M., Cardona I., Corona W., Klemens B., Et al., A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder, Mol Psychiatry, 13, pp. 197-207, (2008)

[3]

Bienvenu O.J., Davydow D.S., Kendler K.S., Psychiatric “diseases” versus behavioral disorders and degree of genetic influence, Psychol Med, 41, pp. 33-40, (2011)

[4]

Biernacka J.M., McElroy S.L., Crow S., Sharp A., Benitez J., Veldic M., Et al., Pharmacogenomics of antidepressant induced mania: a review and meta-analysis of the serotonin transporter gene (5HTTLPR) association, J Affect Disord, 136, pp. e21-e29, (2012)

[5]

Cichon S., Muhleisen T.W., Degenhardt F.A., Mattheisen M., Miro X., Strohmaier J., Et al., Bipolar Disorder Genome Study (BiGS) Consortium. Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder, Am J Hum Genet, 88, pp. 372-381, (2011)

[6]

Body mass index effects on bipolar disorder genetic risk via interaction with TCF7L2 variants. Presented at the 17th Annual Meeting of the International. Society of Bipolar Disorder Jun 3–7, 2015 Toronto, Bipolar Disorders Volume 17 Supplement, (2015)

[7]

Demiroglu S.Y., Skrowny D., Quade M., Schwanke J., Budde M., Gullatz G., Reich-Erkelenz D., Jakob J.J., Falkai P., Rienhoff O., Helbing K., Heilbronner U., Schulze T.G., Managing sensitive phenotypic data and biomaterial in large scale collaborative psychiatric genetic research proejcts: practical considerations, Mol Psychiatry, 12, pp. 1180-1185, (2012)

[8]

Ferreira M.A., O'Donovan M.C., Meng Y.A., Jones I.R., Ruderfer D.M., Jones L., Et al., Wellcome Trust Case Control Consortium. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder, Nat Genet, 40, pp. 1056-1058, (2008)

[9]

Ferrell P.B., McLeod H.L., Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations, Pharmacogenomics, 9, pp. 1543-1546, (2008)

[10]

Frye M.A., Clinical practice: bipolar disorder: a focus on depression, N Engl J Med, 364, pp. 51-59, (2011)

← 1 2 3 4 →